PTPN11 and melanoma: Currently, there are no ongoing clinical trials that evaluate NF1-targeted drugs, but two experimentations regard specifically NF1-mutated melanoma patients, treated with either a MEK inhibitor plus a FAK inhibitor or with RMC-4630, a potent and selective inhibitor of SHP2.